Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Section of Drug Design and Development

Laboratory of Neuroscience

Gerontology Research Center

National Institute on Aging/NIH

USA

Name/email consistency: high

Section of Drug Design and Development, Laboratory of Neuroscience, Gerontology Research Center, National Institute on Aging/NIH, USA. 2002 - 2004
Section of Drug, Design, and Development, Laboratory of Neuroscience, USA. 2002
Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom. 2001

A new Alzheimer's disease interventive strategy: GLP-1. Perry, T.A., Greig, N.H. Curr. Drug. Targets (2004) [Pubmed]
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M., Greig, N.H. J. Neurosci. Res. (2003) [Pubmed]
The glucagon-like peptides: a double-edged therapeutic sword?. Perry, T., Greig, N.H. Trends Pharmacol. Sci. (2003) [Pubmed]
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. Perry, T., Lahiri, D.K., Chen, D., Zhou, J., Shaw, K.T., Egan, J.M., Greig, N.H. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. Perry, T., Haughey, N.J., Mattson, M.P., Egan, J.M., Greig, N.H. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
Behavioural, histological and immunocytochemical consequences following 192 IgG-saporin immunolesions of the basal forebrain cholinergic system. Perry, T., Hodges, H., Gray, J.A. Brain Res. Bull. (2001) [Pubmed]